Erythrokinetic mechanism(s) causing the "late anemia" of hemolytic disease of the fetus and newborn

被引:1
|
作者
Christensen, Robert D. [1 ,2 ]
Bahr, Timothy M. [1 ,2 ]
Ohls, Robin K. [2 ]
Ilstrup, Sarah J. [3 ]
Moise Jr, Kenneth J. [4 ,5 ]
Lopriore, Enrico [6 ]
Meznarich, Jessica A. [7 ]
机构
[1] Women & Newborns Res, Intermt Hlth, Murray, UT 84107 USA
[2] Univ Utah, Dept Pediat, Div Neonatol, Salt Lake City, UT 84112 USA
[3] Dept Pathol, Transfus Med, Intermt Hlth, Murray, UT USA
[4] Dell Childrens Med Ctr, Comprehens Fetal Care Ctr, Austin, TX USA
[5] Dell Med Sch, Dept Womens Hlth, Austin, TX USA
[6] Leiden Univ Med Ctr, Div Neonatol, Leiden, Netherlands
[7] Univ Utah, Dept Pediat, Div Hematol Oncol, Salt Lake City, UT USA
关键词
LATE HYPOREGENERATIVE ANEMIA; RECOMBINANT-HUMAN-ERYTHROPOIETIN; TOP-UP TRANSFUSIONS; INTRAUTERINE TRANSFUSION; BREAST-MILK; ANTI-D; SUPPRESSION; PREVENTION; ANTIBODIES; MANAGEMENT;
D O I
10.1038/s41372-024-01872-z
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
A transfusion-requiring "late anemia" can complicate the management of neonates convalescing from hemolytic disease of the fetus and newborn (HDFN). This anemia can occur in any neonate after HDFN but is particularly prominent in those who received intrauterine transfusions and/or double-volume exchange transfusions. Various reports describe this condition as occurring based on ongoing hemolysis, either due to passive transfer of alloantibody through breast milk or persistence of antibody not removed by exchange transfusion. However, other reports describe this condition as the result of inadequate erythrocyte production. Both hypotheses might have merit, because perhaps; (1) some cases are primarily due to continued hemolysis, (2) others are primarily hypoproductive, and (3) yet others result from a mixture of these two mechanisms. We propose prospective collaborative studies that will resolve this issue by serially quantifying end-tidal carbon monoxide. Doing this will better inform the assessment and treatment of neonates recovering from HDFN.
引用
收藏
页码:916 / 919
页数:4
相关论文
共 50 条
  • [1] ETIOLOGY OF LATE ANEMIA OF HEMOLYTIC DISEASE OF NEWBORN
    POCHEDLY, C
    PALLADINO, N
    CLINICAL MEDICINE/US, 1971, 78 (02): : 30 - +
  • [2] Late anemia in a newborn with Rh hemolytic disease
    Siliprandi, N
    Borroni, C
    Ventura, ML
    Zapparoli, B
    Rubaltelli, FF
    RIVISTA ITALIANA DI PEDIATRIA-ITALIAN JOURNAL OF PEDIATRICS, 1998, 24 (01): : 160 - 162
  • [3] Anti-K18 Causing Hemolytic Disease of the Fetus and Newborn
    O'Leary, M. F.
    Larimore, K. S.
    Hue-Roye, K.
    Pirman, M.
    Hancock, H.
    Sausais, L.
    Lomas-Francis, C.
    TRANSFUSION, 2011, 51 : 156A - 156A
  • [4] HEMOLYTIC DISEASE OF FETUS AND NEWBORN
    LEVINE, P
    POLLACK, W
    MEDICAL CLINICS OF NORTH AMERICA, 1965, 49 (06) : 1647 - +
  • [5] Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn
    Delaney, Meghan
    Matthews, Dana C.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 146 - 151
  • [6] The management of hemolytic disease in the fetus and newborn
    Bowman, J
    SEMINARS IN PERINATOLOGY, 1997, 21 (01) : 39 - 44
  • [7] HEMOLYTIC DISEASE OF FETUS AND NEWBORN INFANT
    不详
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1960, 173 (10): : 1163 - 1164
  • [8] Laboratory Monitoring of Mother, Fetus, and Newborn in Hemolytic Disease of Fetus and Newborn
    Dziegiel, Morten Hanefeld
    Krog, Grethe Risum
    Hansen, Anne Todsen
    Olsen, Marianne
    Lausen, Birgitte
    Norgaard, Lone Nikoline
    Bergholt, Thomas
    Rieneck, Klaus
    Clausen, Frederik Banch
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2021, 48 (05) : 306 - 315
  • [9] Janssen's nipocalimab tackles hemolytic disease of the fetus and newborn
    Carvalho, Thiago
    NATURE MEDICINE, 2023, 29 (04) : 757 - 758
  • [10] Janssen’s nipocalimab tackles hemolytic disease of the fetus and newborn
    Thiago Carvalho
    Nature Medicine, 2023, 29 : 757 - 758